Effect of Oral and Transdermal Estrogen Replacement Therapy on Hemostatic Variables Associated With Venous Thrombosis

Author:

Post Marinka S.1,Christella M.1,Thomassen L.G.D.1,van der Mooren Marius J.1,van Baal W. Marchien1,Rosing Jan1,Kenemans Peter1,Stehouwer Coen D.A.1

Affiliation:

1. From Project “Aging Women” and the Institute for Cardiovascular Research-Vrije Universiteit, Departments of Obstetrics & Gynecology (M.S.P., M.J.v.d.M., W.M.v.B., P.K.) and Internal Medicine (C.D.A.S.), VU University Medical Center, Amsterdam, and Department of Biochemistry, Cardiovascular Research Institute Maastricht (M.C.L.G.D.T., J.R.), Maastricht University, Maastricht, The Netherlands.

Abstract

Objective— The purpose of this study was to investigate whether the effect of transdermal estrogen therapy in postmenopausal women differs from that of oral therapy with regard to resistance to activated protein C (APC), an important risk factor for venous thrombosis, and levels of related proteins, such as protein S, protein C, and prothrombin. Methods and Results— In a randomized, double-blind, placebo-controlled study, 152 healthy hysterectomized postmenopausal women received daily either placebo (n=49), transdermal 17β-estradiol (E 2 ) 50 μg (tE 2 group, n=33), oral E 2 1 mg (oE 2 group, n=37), or oral E 2 1 mg combined with gestodene 25 μg (oE 2 +G group, n=33) for 13 28-day treatment cycles, followed by 4 cycles of placebo for each group. Plasma samples were collected at baseline and in cycles 4, 13, and 17. In cycle 13, significant increases versus baseline and placebo were found in normalized APC sensitivity ratios (nAPCsr) in all treated groups (tE 2 , +26.9%; oE 2 , +102.7%; oE 2 +G, +69.9%). Increases in nAPCsr were significantly higher in the oral treatment groups than in the tE 2 group. In addition, compared with baseline and placebo, after 13 cycles, decreases were observed in total protein S (tE 2 , −4.1%; oE 2 , −7.9%; oE 2 +G, −5.8%), free protein S (tE 2 , −7.1%; oE 2 , −8.4%; oE 2 +G, −5.2%), and protein C in the oE 2 +G group (−6.4%), but these changes did not explain the increase in nAPCsr. Changes in prothrombin were small and also did not affect the nAPCsr. Conclusions— Increases were observed in resistance to APC, which were more pronounced in the oral treatment groups than in the transdermal group. The increase in resistance to APC was not explained by changes in protein S, protein C, or prothrombin and may contribute to the increased incidence of venous thrombosis in users of hormone replacement therapy.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3